Definitive Contract 75N93020C00009
Award Date 6/1/20
Potential Completion Date 5/31/25
Potential Value $1.6M
Federal Agency
Ultimate Awardee
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Madison, WI 53705, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded The Medical College of Wisconsin, Inc. a $3.28M definitive contract on July 1, 2023, to conduct research on the mitigation of multi-organ delayed effects of acute radiation exposure (DEARE) using the ACE-inhibitor lisinopril. The cost-no-fee contract, which extends through June 30, 2027, represents work performed in Wauwatosa, Wisconsin, and originated from a pre-solicitation notice issued in November 2021 seeking proposals for...
- This is a $81,904,328.96 cost-no-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to the University of Maryland, Baltimore (UMB) for radiation/nuclear medical countermeasure product development support services. The contract supports the development of medical countermeasures against radiation and nuclear threats, which aligns with NIAID's mission to conduct and support research to...
- The National Institute of Allergy and Infectious Diseases (NIAID) of the Department of Health and Human Services awarded a $6,620,728 cost-plus-fixed-fee contract to Xequel Bio, Inc. (doing business as FSR) to develop a topical therapeutic called GRANEXIN to mitigate cutaneous radiation injury. This contract was awarded under a prior NIAID Broad Agency Announcement that sought proposals for advanced development of medical countermeasures, including those targeting radiation exposure. The...
- This is a $6,150,127.06 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to BCN Biosciences LLC for the development of medical countermeasures to mitigate and/or treat radiation-induced lung injury after a radiological/nuclear incident. The contract has an ultimate completion date of April 30, 2019 and does not have a set-aside designation. Based on the major program code, this contract supports NIAID's efforts to develop...
- This federal contract award is for the "Characterizing and Improving Humanized Immune System Mouse Models (IMM-HIS)" project, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to The Trustees of Columbia University in the City of New York, the prime contractor. The contract has a ceiling value of $2,198,718.97 and is a definitive contract with a cost-no-fee pricing type. The contract is not set aside and is meant to support research to develop safe and...
- This is a federal contract award to the University of Maryland, Baltimore (UMB) from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The contract, valued at $63,079,974.98, is for providing product development support services related to medical countermeasures against radiological threats. The contract was awarded on September 30, 2005 and has a completion date of November 21, 2013. There is no set-aside designation for this award,...
- The University of Wisconsin System was awarded a $26,466,874.00 federal contract by the National Institute of Allergy and Infectious Diseases (NIAID) to provide a 1-year no-cost extension to the existing contract. This contract was a definitive contract with a cost-no-fee pricing type. The contract did not have a set-aside designation. As the prime contractor, the University of Wisconsin System, through its University of Wisconsin - Madison division operating as Research and Sponsored...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to SRI International, a non-profit research and development organization. The contract is for $575,362.67 and is a delivery order under a larger contract vehicle. The purpose is to support the development of radiation/nuclear medical countermeasures. This work aligns with NIAID's mission to conduct and support biomedical research,...
- This is a cost-plus-fixed-fee delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to SRI International, a non-profit research and development institute. The contract is for $6,245,298.00 to provide radiation/nuclear medical countermeasure (MCM) product development support services, specifically animal model development and initial efficacy testing of candidate MCMs. This task order is part...
- Duke University's Office of Research Administration was awarded a $3.5M definitive contract by the National Institute of Allergy and Infectious Diseases (NIAID) on March 1, 2024, to conduct research on promoting T cell recovery after radiation injury using long-acting interleukin 7. The contract, which operates on a cost reimbursement basis with no fee component, is scheduled for completion by February 28, 2027, and will be performed at Duke's Durham, North Carolina facility. This award...